Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng, Bin He
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Thomas Powles, Kobe Yuen, Silke Gillessen, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 144-153
Open Access | Times Cited: 169
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states
Hanbing Song, H Weinstein, Paul Allegakoen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 156
β−Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives
Jürgen Wess, Antwi‐Boasiako Oteng, Osvaldo Rivera‐Gonzalez, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 854-884
Open Access | Times Cited: 55
Rare ginsenosides: A unique perspective of ginseng research
Wenxiang Fan, Linhong Fan, Ziying Wang, et al.
Journal of Advanced Research (2024) Vol. 66, pp. 303-328
Open Access | Times Cited: 28
Development and prevalence of castration-resistant prostate cancer subtypes
Jordan E. Vellky, William A. Ricke
Neoplasia (2020) Vol. 22, Iss. 11, pp. 566-575
Open Access | Times Cited: 99
Tumor-on-chip modeling of organ-specific cancer and metastasis
Nuala Del Piccolo, Venktesh S. Shirure, Ye Bi, et al.
Advanced Drug Delivery Reviews (2021) Vol. 175, pp. 113798-113798
Open Access | Times Cited: 82
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Luca Braglia, Manuela Zavatti, Marco Vinceti, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2020) Vol. 1867, Iss. 9, pp. 118731-118731
Open Access | Times Cited: 81
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Aaron Waddell, Haojie Huang, Daiqing Liao
Cancers (2021) Vol. 13, Iss. 12, pp. 2872-2872
Open Access | Times Cited: 72
Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology
Milad Ashrafizadeh, Shahin Aghamiri, Shing Cheng Tan, et al.
Nano Today (2022) Vol. 45, pp. 101532-101532
Open Access | Times Cited: 60
Calcium signalling pathways in prostate cancer initiation and progression
Roberto Silvestri, Vanessa Nicolì, Priyadarsini Gangadharannambiar, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 9, pp. 524-543
Closed Access | Times Cited: 26
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 15
Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance
Dexin Xu, Wenhai Wang, Duo Wang, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 2, pp. 388-406
Open Access | Times Cited: 12
Cell Membrane‐Camouflaged Chitosan‐Polypyrrole Nanogels Co‐Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer
Qiuyu Yu, Yue Gao, Waicong Dai, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 20
Closed Access | Times Cited: 12
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer
Ayodeji Folorunsho Ajayi, Mega Obukohwo Oyovwi, Oyedayo Phillips Akano, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Fionnuala Crowley, Michelle Sterpi, Conor Buckley, et al.
Research and Reports in Urology (2021) Vol. Volume 13, pp. 457-472
Open Access | Times Cited: 49
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Jian Huang, Biyun Lin, Benyi Li
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models
Mirian Galliote Morale, Rodrigo Esaki Tamura, Ileana Gabriela Sanchez Rubio
Biomolecules (2022) Vol. 12, Iss. 3, pp. 357-357
Open Access | Times Cited: 31
Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation
Di Cui, Jianneng Li, Ziqi Zhu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 20
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer
Amy R. Leslie, Shu Ning, Cameron M. Armstrong, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108984-108984
Open Access | Times Cited: 7
Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review
Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen‐van Grunsven, et al.
Cancer Treatment Reviews (2020) Vol. 89, pp. 102069-102069
Open Access | Times Cited: 45
Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, et al.
Theranostics (2020) Vol. 11, Iss. 2, pp. 958-973
Open Access | Times Cited: 41
Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
Linrong Chen, Liuquan Han, Shujun Mao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 216, pp. 113307-113307
Closed Access | Times Cited: 40
Novel Functionalized Spiro [Indoline-3,5′-pyrroline]-2,2′dione Derivatives: Synthesis, Characterization, Drug-Likeness, ADME, and Anticancer Potential
Mohd Asif, Sahir Sultan Alvi, Tazeen Azaz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7336-7336
Open Access | Times Cited: 16
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer
Neeraj Agarwal, Fred Saad, Arun Azad, et al.
Future Oncology (2023) Vol. 20, Iss. 9, pp. 493-505
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top